Fusions in neuregulin 1 (NRG1) and neuregulin 2 (NRG2) genes are molecular features of non-small cell lung cancer. These rearrangements enhance ectopic expression of the NRG/ErbB receptor‐ligand and induce the triggering of downstream pathways.
[Expert Opinion On Therapeutic Targets]